Cagrilintide with retatrutide: what the evidence actually shows

Last updated 2026-07-25

Is there a clinical trial testing cagrilintide with retatrutide together?

No. As of this writing, there is no registered clinical trial that combines cagrilintide with retatrutide as a co-administered regimen. Retatrutide's own trial program is registered on ClinicalTrials.gov as a standalone triple agonist, tested against placebo and against itself at different doses, not against or alongside cagrilintide ^{[1] [2] [3]}. Cagrilintide, a long-acting amylin analog, has its own separate development track. Its most advanced published data comes from combination with semaglutide (the drug pairing known as CagriSema), not with retatrutide. Nobody has run a head-to-head or combination arm testing cagrilintide plus retatrutide in humans, and no such data exists in any journal or trial registry to cite here. If you see a vendor or forum post claiming '48% weight loss' or similar from a cagrilintide-retatrutide stack, that number isn't coming from a controlled trial. It's coming from anecdote, extrapolation, or marketing copy. This matters because the entire appeal of a hypothetical amylin-plus-triple-agonist stack rests on plausible biology, not demonstrated outcomes. Amylin analogs slow gastric emptying and increase satiety through a different receptor system than GIP/GLP-1/glucagon agonism. Stacking two different mechanisms sounds reasonable on paper. But 'sounds reasonable' is not evidence, and the gap between mechanism and measured outcome in humans is exactly where drug development lives or dies.

What does retatrutide alone actually do, based on real trial data?

The best public data on retatrutide comes from a phase 2 obesity trial published in the New England Journal of Medicine. At the 12 mg weekly dose, participants lost a mean of 24.2% of body weight at 48 weeks, compared to 2.1% in the placebo group ^[4]. That is a single phase 2 result, not a phase 3 confirmation, and the trial dosed retatrutide by weekly subcutaneous injection, exactly as registered under NCT04881760 ^[1]. Retatrutide is a triple agonist. It activates receptors for GIP, GLP-1, and glucagon at once. That sets it apart mechanistically from semaglutide, which is GLP-1 only, and tirzepatide, which hits GIP and GLP-1 but not the glucagon receptor ^[4]. The added glucagon receptor activity is the theoretical reason retatrutide has shown larger weight reductions in early trials than either of the approved incretin drugs, since glucagon receptor agonism increases energy expenditure on top of appetite suppression. Retatrutide has since moved into later-phase registered trials, including NCT05929066 and NCT05882045, whose public records list enrollment criteria, comparator arms, and endpoints ^{[2] [3]}. It's also been studied in registered type 2 diabetes trials beyond the obesity program, so the evidence base is broader than weight loss alone ^[1]. None of this constitutes FDA approval. A search of the Drugs@FDA database for the generic name retatrutide returns no approved product for any indication ^[5].

Why can't cagrilintide with retatrutide be legally compounded or prescribed?

Because neither ingredient clears the legal bar for compounding, and retatrutide specifically fails on multiple independent grounds. Section 503A of the Food, Drug and Cosmetic Act allows a compounding pharmacy to use a bulk drug substance only through a strict cascade: the substance must comply with an applicable USP or NF monograph if one exists; if no monograph exists, it must be a component of an FDA-approved drug; only if neither of those applies can it come from the 503A Bulks List ^[6]. Retatrutide has no USP monograph, is not a component of any approved drug, and does not appear on that list ^[7]. The final 503A Bulks List, codified at 21 CFR 216.23, contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[7]. No peptide is on that list, and retatrutide has never been nominated for it ^[8]. The parallel list governing outsourcing facilities, the 503B bulks list at 21 CFR 216.24, also does not include retatrutide ^[9]. Separately, even if an ingredient did qualify under the cascade, 503A requires that every bulk drug substance be manufactured by an establishment registered under section 510 of the FD&C Act and accompanied by a valid certificate of analysis ^[6]. Research-use-only material sold by unregistered suppliers, which is where essentially all gray-market retatrutide and cagrilintide originate, fails this requirement regardless of anything else. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an approved application, which is the basic statutory reason retatrutide is unavailable outside a clinical trial ^[10]. There is no lawful path for a US pharmacist to compound it, stack it, or dispense it today.

Does a research-use-only label make buying it legal?

No. FDA has been explicit that a 'research use only' or 'not for human consumption' disclaimer does not change a product's legal status if the seller's actual marketing establishes intended use as a drug. Intended use is judged by labeling claims, advertising, and statements made by the seller, not by a disclaimer buried in fine print ^[11]. In a March 2026 warning letter to Gram Peptides, FDA wrote that despite RUO-style labeling, 'evidence from the company's website established that its products were intended to be drugs for human use,' and the letter specifically named retatrutide marketed on that site ^[12]. If a vendor's own page describes weight loss outcomes, dosing schedules, or therapeutic benefits for humans, that marketing language is what determines drug status under the law, not the disclaimer sitting next to it. This is why 'RUO' stickers on cagrilintide or retatrutide vials sold online don't protect either the seller or the buyer legally. It's also why buying either compound this way is not a gray area. It's simply outside the law.

Has any peptide combination like this been considered for legal compounding?

FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to consider seven peptides for possible inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[5]. Retatrutide was not among them, and it has never been nominated for that list ^[8]. Cagrilintide wasn't part of that docket either. Even a favorable advisory committee vote wouldn't create an automatic compounding pathway. Advisory committee recommendations are non-binding, and actually adding a substance to the 503A Bulks List requires full notice-and-comment rulemaking, a process that takes years, not months ^[5]. So even for the seven peptides that did get a hearing in 2026, nothing changes overnight. For retatrutide and cagrilintide, which weren't even on the agenda, there is no active regulatory process moving toward legal compounding at all right now.

What about tesamorelin with retatrutide, or a sermorelin and retatrutide stack?

Same legal problem, different peptides. Tesamorelin is FDA-approved (as Egrifta) for a specific, narrow indication: reduction of excess abdominal fat in HIV-associated lipodystrophy. It is not approved for general weight loss, and pairing it with retatrutide has no trial data behind it whatsoever. Sermorelin is a growth hormone-releasing hormone analog sometimes used off-label by anti-aging clinics; it also has no registered trial testing it alongside retatrutide. The retatrutide side of any 'stack' still runs into the same wall described above: no FDA approval, no monograph, no Bulks List entry, no legal compounding pathway ^{[6] [7]}. Adding tesamorelin or sermorelin into the mix doesn't change retatrutide's legal status. It just adds a second unapproved-for-this-use compound and a second set of unknowns about interaction effects that nobody has studied in a controlled setting. The same logic applies to a retatrutide peptide with testosterone stack sometimes advertised online: testosterone therapy itself is FDA-approved and prescribable for diagnosed hypogonadism, but combining it with retatrutide has never been tested in a trial, and the retatrutide component remains just as illegal to obtain outside research whether or not it's paired with testosterone.

What are the real, lawful options right now instead of a peptide stack?

If you're dealing with obesity or a related metabolic condition, there are FDA-approved incretin drugs with actual safety databases behind them. Semaglutide is approved and marketed as Ozempic and Wegovy. Tirzepatide is approved as Mounjaro and Zepbound. Both have published long-term safety and efficacy data and can be legally prescribed today ^[13]. There's also a newer oral option. Orforglipron, an oral GLP-1 receptor agonist, was approved under the brand name Foundayo (NDA 220934) in six strengths ranging from 0.8 mg to 17.2 mg ^[14]. That gives patients who want to avoid injections, or who were specifically drawn to retatrutide or cagrilintide because gray-market vendors made them sound like an accessible experimental option, an actual FDA-approved oral incretin instead. NIDDK, the federal government's diabetes and digestive disease research institute, publishes neutral guidance on evidence-based weight management approaches that don't depend on any single drug being available ^[15]. That's a reasonable starting point if you want a clinician conversation grounded in what's actually proven, rather than in a mechanism that merely sounds promising. For deeper background specifically on retatrutide's trial evidence and how it compares to other incretins, see our coverage of retatrutide peptide and our comparisons hub.

If someone is already using retatrutide, what dosing did trials actually use?

This is worth stating plainly: no clinician can lawfully prescribe retatrutide outside a registered clinical trial in the United States right now, because it holds no FDA approval ^{[5] [10]}. What follows describes what the phase 2 trial protocol used, attributed directly to that trial, not a recommendation for anyone to replicate outside supervised research. In the NEJM phase 2 obesity trial, retatrutide was dosed by weekly subcutaneous injection, with dose arms escalating up to 12 mg, the dose that produced the 24.2% mean weight loss at 48 weeks ^{[4] [1]}. The trial protocol included a dose-escalation schedule specifically to manage gastrointestinal tolerability, a common issue with incretin-class drugs during the early weeks of treatment. Cagrilintide, in its own separate trials (not combined with retatrutide), has similarly been dosed by weekly subcutaneous injection with dose titration. Any numbers circulating in gray-market or forum contexts about 'stacking doses' of cagrilintide with retatrutide come from neither of these registered protocols. They're not backed by a trial, an FDA-reviewed protocol, or a clinician overseeing bloodwork and adverse event monitoring. If you're seeing dosing charts for a cagrilintide-retatrutide combination online, understand that nobody ran the safety study to generate those numbers responsibly. For general reference on how retatrutide dosing has been studied in trials, see our retatrutide dosage chart and notes on reconstitution, which cover trial-reported information only, not self-administration advice.

What are the safety unknowns specific to combining these compounds?

Because no trial has tested cagrilintide with retatrutide together, there is no published safety data on the combination at all. That's the honest, complete answer. Each compound individually carries known and studied side effect profiles from its own trials (retatrutide's GI-related effects appear in the NEJM trial data ^[4]), but nobody has data on what happens when both mechanisms are active in the same person at the same time. Amylin analogs and GIP/GLP-1/glucagon triple agonists both slow gastric motility and suppress appetite through overlapping but distinct pathways. Compounding two appetite-suppressing, GI-motility-affecting mechanisms without any trial oversight raises real questions about severe GI events, dehydration, and interaction effects, none of which have been studied. Add in the fact that gray-market material isn't manufactured under section 510 registration or accompanied by a valid certificate of analysis ^[6], and you're combining an unstudied drug interaction with unverified drug purity and unverified dose. For a full breakdown of what is documented about retatrutide's known side effects from actual trial data, see our retatrutide side effects coverage.

What about personal importation, is that a legal loophole?

Not really a reliable one. FDA publishes a specific policy on personal importation of unapproved drugs, and it applies directly to anyone considering ordering retatrutide, cagrilintide, or a combination product from an overseas source . The policy is discretionary enforcement guidance, not a legal right to import unapproved drugs, and FDA can and does seize shipments of unapproved drug products at the border. Even where enforcement discretion might apply to a small personal quantity, importation doesn't solve the underlying problems: no clinician oversight, no verified purity, no dosing protocol backed by data, and no legal recourse if something goes wrong. It also doesn't change retatrutide's fundamental status under 21 U.S.C. 355 as a drug that cannot be lawfully introduced into US commerce without FDA approval ^[10]. Retatrutide Report exists to explain exactly this kind of gap between what trial headlines promise and what a person can lawfully and safely obtain today.

Frequently asked questions

Can I legally buy cagrilintide with retatrutide as a peptide stack?

No. Retatrutide has no FDA approval and is not on the 503A Bulks List, so no US pharmacy can lawfully compound it ^[8][10]. Cagrilintide's only approved combination use is with semaglutide outside the US. Vendors selling a 'cagri peptide with retatrutide' stack are operating outside FDA's legal framework regardless of any research-use-only label they attach.

Has cagrilintide with retatrutide been tested in a clinical trial?

No published or registered trial combines the two. Retatrutide's registered trials (NCT04881760, NCT05929066, NCT05882045) test it alone or against placebo, not alongside cagrilintide ^[1][2][3][5]. Any claimed results for the combination online come from anecdote or marketing, not controlled research.

What did the retatrutide phase 2 trial actually show?

The phase 2 obesity trial published in NEJM found a mean 24.2% weight reduction at the 12 mg weekly dose at 48 weeks, versus 2.1% for placebo ^[4]. That's a single phase 2 result in a defined population, dosed by weekly subcutaneous injection, not a confirmed phase 3 outcome or an approved therapy.

Is retatrutide FDA-approved for any use?

No. A Drugs@FDA search for the generic name retatrutide returns no approved product for any indication ^[8]. It remains investigational, studied in registered obesity and type 2 diabetes trials, but not available by prescription outside those trials.

Why isn't retatrutide on the FDA compounding bulks list?

The 503A Bulks List at 21 CFR 216.23 contains exactly six non-peptide substances, and retatrutide isn't one of them ^[10]. It also has no USP monograph and isn't a component of any approved drug, so it fails all three legs of the 503A ingredient cascade required under 21 U.S.C. 353a ^[9].

Does a 'research use only' label make retatrutide or cagrilintide legal to sell?

No. FDA has stated that RUO disclaimers don't override actual marketing claims. A March 2026 warning letter to Gram Peptides found the company's own website established intended use as a human drug despite RUO labeling, and specifically cited retatrutide ^[16]. Intended use is judged by marketing language, per 21 CFR 201.128 ^[15].

What is tesamorelin with retatrutide, and is it studied?

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, not general weight loss. No trial has tested tesamorelin combined with retatrutide. Retatrutide itself remains investigational regardless of what it's paired with, so this combination carries the same legal and safety unknowns as any other retatrutide stack.

Is a sermorelin and retatrutide stack backed by any evidence?

No. Sermorelin is a growth hormone-releasing hormone analog sometimes used off-label in anti-aging settings. There's no registered trial testing it with retatrutide. Combining an off-label peptide with an investigational triple agonist that has no approved indication leaves this stack entirely outside documented clinical evidence.

What FDA-approved alternatives exist instead of an unapproved peptide stack?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved incretin drugs with published safety data ^[18]. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo (NDA 220934) in six strengths from 0.8 mg to 17.2 mg, giving an approved oral option too ^[19].

Could retatrutide ever get added to the 503A Bulks List?

It's possible in theory but nothing is pending. FDA's Pharmacy Compounding Advisory Committee reviewed seven other peptides in July 2026, and retatrutide wasn't among them and has never been nominated ^[17][11]. Even a favorable vote wouldn't create automatic legality; adding a substance requires full notice-and-comment rulemaking ^[17].

Is it legal to import retatrutide or cagrilintide for personal use from overseas?

FDA's personal importation policy addresses this directly, and it is discretionary enforcement guidance, not a guaranteed legal right ^[21]. Shipments of unapproved drugs can still be seized. Importing also doesn't resolve the underlying safety issue of unverified purity and no clinician oversight.

What does retatrutide's triple agonist mechanism mean compared to semaglutide or tirzepatide?

Retatrutide activates GIP, GLP-1, and glucagon receptors together. Semaglutide is GLP-1 only, and tirzepatide combines GIP and GLP-1 without glucagon activity ^[4]. The added glucagon receptor action is the proposed reason for retatrutide's larger early weight loss signal, though this remains a phase 2 finding, not a confirmed long-term result.

Sources

1. ClinicalTrials.gov, NCT04881760: Registered phase 2 retatrutide obesity trial (LY3437943) lists dose arms and route studied, standalone, not combined with cagrilintide
2. ClinicalTrials.gov, NCT05929066: Later-phase retatrutide trial registration lists enrollment criteria, comparators, and endpoints
3. ClinicalTrials.gov, NCT05882045: Second later-phase retatrutide trial registration gives independent record of dosing and design under study
4. Jastreboff AM et al., New England Journal of Medicine, 2023: Retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks vs 2.1% placebo; triple agonist mechanism at GIP, GLP-1, glucagon receptors
5. Drugs@FDA, FDA-approved drug products database: Search for generic name retatrutide returns no FDA-approved product for any indication
6. 21 U.S.C. 353a(b)(1)(A)(i), Cornell Law: Section 503A ingredient cascade requires monograph compliance, then FDA-approved drug component, then Bulks List, in that order
7. 21 CFR 216.23, eCFR: Final 503A Bulks List contains exactly six substances, no peptide, retatrutide not included
8. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Public nominations list shows retatrutide has never been nominated for the 503A Bulks List
9. 21 CFR 216.24, eCFR: Separate 503B outsourcing facility bulks list also does not include retatrutide
10. 21 U.S.C. 355, Cornell Law: New drugs cannot be introduced into interstate commerce without an approved application
11. 21 CFR 201.128, eCFR: Intended use is grounded in labeling claims, advertising, and seller statements, not disclaimers
12. Federal Register, Docket FDA-2025-N-6895, published 16 April 2026: Advisory committee reviewed seven peptides (not retatrutide) in July 2026; committee votes are non-binding and require rulemaking to take effect
13. Drugs@FDA, NDA 220934: Orforglipron approved as Foundayo in six strengths from 0.8 mg to 17.2 mg
14. NIDDK, Weight Management: Federal guidance on evidence-based weight management as neutral reference for patients
15. FDA, Personal Importation: FDA's personal importation policy applies to anyone considering ordering an investigational drug from overseas